financetom
Business
financetom
/
Business
/
Why Did Salarius (SLRX) Shares Soar Over 23% After-Hours?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Did Salarius (SLRX) Shares Soar Over 23% After-Hours?
Nov 11, 2025 7:48 PM

Salarius Pharmaceuticals Inc. ( SLRX ) shares surged 23.65% in after-hours trading on Tuesday, closing at $1.21. The Houston-based biopharmaceutical company's stock jumped after it released pricing details for its underwritten public offering.

Check out the current price of SLRX stock here.

According to Benzinga Pro data, the stock dropped 51% in the regular trading session to close Tuesday at $0.98.

$7 Million Offering Details

Salarius stated in a press release on Tuesday that it priced an underwritten public offering with the goal of raising roughly $7 million in gross proceeds before fees.

The offering comprises 2.51 million common stock shares and pre-funded warrants to purchase 2.15 million shares at a combined offering price of $1.50 per share with accompanying Series A and Series B warrants.

Warrant Structure and Terms

The exercise price for both warrant series is $1.50. Series B warrants have a one-year exercise window, whereas Series A warrants are exercisable for five years after issuance. The filing states that the warrants have fixed pricing with no variable pricing features.

Merger-Contingent Closing

The completion of Salarius’ proposed business combination with Decoy Therapeutics Inc., a preclinical-stage biotechnology company, is a prerequisite for the offering’s closing, which is anticipated on Wednesday.

Ladenburg Thalmann & Co. Inc. serves as the sole book-running manager.

Salarius plans to use the proceeds to fund research programs, repay Decoy's promissory notes, and cover working capital needs.

Stock Performance

The stock of the clinical-stage company is down 96.25% year to date.

The company has a market capitalization of $1.03 million and an average daily trading volume of 318,090 shares.

Benzinga Edge Stock Rankings indicate that SLRX has a negative price trend across all time frames. Track the performance of other players in this segment.

Read Next:

Cathie Wood Goes Big On Alibaba With $25 Million Share Purchase, Scales Back On This Social Media Stock

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved